US92941V3087 - Common Stock
VYNE THERAPEUTICS INC
NASDAQ:VYNE (5/3/2024, 7:25:56 PM)
2.62
+0.12 (+4.8%)
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 12 full-time employees. The company went IPO on 2018-01-25. The firm is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. Its FMX114 is investigational combination gel formulation of tofacitinib and fingolimod that is designed to address both the source and cause of inflammation in atopic dermatitis (AD). The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans.
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807
P: 18007757936
CEO: David Domzalski
Employees: 12
Website: https://vynetherapeutics.com/
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01,...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a...
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
Vyne Therapeutics (VYNE) reported positive Phase 1b biomarker data for its vitiligo drug candidate VYN201. Read more here.
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Here you can normally see the latest stock twits on VYNE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: